DRUG NAME
INDICATION/CONTRAINDICATION
NAME: Serious or severe infections due to susceptible methicillin-resistant (betalactam-resistant) staphylococci in BRAND NAME: Vancocin penicillin-allergic penicillin-allergic patients; patients who cannot receive or have failed to CLASSIFICATION : respond to other drugs, including antibiotic penicillins and cephalosporins; cephalosporins; and for infections due to vancomycinDOSAGE: premixed susceptible organisms resistant to solution 500 mg per 100 mL other antimicrobials. Staphylococcal endocarditis, endocarditis, including septicemia, and FREQUENCY: q 8 infections of the lower respiratory tract, bone, and skin and skin ROUTE: IV injection structure. Streptococcal endocarditis due to S. viridans or S. bovis as monotherapy or in combination with an aminoglycoside. Enterococcal endocarditis endocarditis due to E. faecalis in combination with an aminoglycoside. Diphtheroid endocarditis. Early-onset prosthetic valve endocarditis due to S.epidermidis or diphtheroids diphtheroids in combination with rifampin, or an aminoglycoside, aminoglycoside, or both. GENERIC vancomycin
SIDE EFFECTS/ADVERSE EFFECT
Cardiovascular : Hypotension. CNS: Headache (7%); fatigue (5%); dizziness, vertigo (rare). Dermatologic: Drug rash with eosinophilia and systemic symptoms, exfoliative dermatitis, pruritus, rash, Stevens-Johnson syndrome, TEN, urticaria, vasculitis (postmarketing). EENT: Hearing loss; tinnitus (rare). GI: Nausea (17%); abdominal pain (15%); diarrhea, vomiting (9%); flatulence (8%); antibiotic-associated antibiotic-associated colitis. Genitourinary: Urinary tract infection (8%); nephrotoxicity including increased blood creatinine, renal failure, and renal impairment (5%); increased BUN; interstitial nephritis, renal failure (rare). Hematologic: Reversible agranulocytosis;eosinophilia, reversibleneutropenia, thrombocytopenia (postmarketing). Respiratory: Dyspnea, wheezing. Miscellaneous: Hypokalemia
NURSING CONSIDERATION
Reconstituted powder must be further diluted prior to administration. administration. Concentrations of no more than 5 mg/mL and rates of no more than 10 mg/min are recommended in adults. Administer over a period of no less than 60 min by intermittent infusion. Other patient factors, such as age or obesity, may call for modification of the usual IV daily dose. The total daily IV dosage may be lower in neonates. In premature infants, vancomycin Cl decreases as postconceptional postconceptional age decreases. Therefore, longer dosing intervals may be necessary in premature infants. Close monitoring of serum concentrations of vancomycin may be warranted in these patients.
(13%); pyrexia (9%); back pain, peripheral edema (6%); anaphylaxis, chills, drug fever, hypotension, red man syndrome (flushing of the face, neck, upper chest, and extremities) (postmarketing).
Certain parenteral products may be administered orally. Dilute in 1 oz of water. Common flavoring syrups may be added to the solution. The diluted solution may be given via nasogastric tube. Thaw frozen Galaxy containers at room temperature or under refrigeration. Do not thaw by water bath immersion or by microwave. Monitor hearing, blood, renal function. Monitor vancomycin serum concentrations closely. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
